Cervical Cancer Overview

Principles

Definition

Cervical cancer is the academic and clinical field focused on the malignant neoplasm originating from the uterine cervix, comprising comprehensive research into its etiology, pathogenesis, epidemiology, prevention strategies (including vaccination and screening), diagnostic methodologies, and therapeutic interventions, thereby addressing a significant global health burden and public health priority.

Ontological type

Etiology and Risk Factors

Epidemiology

Screening Strategies

Key developments

Key Figures

Histology-Guided Management era

Harald zur Hausen [1] conducted research across institutions such as the University of Pennsylvania [3] and the University of Würzburg [4] during the Histology-Guided Management era (1948-1984). Harald zur Hausen [1] identified a papillomavirus DNA from a cervical carcinoma in a 1983 study [7], a finding that underpinned histology-guided risk stratification and management in this era. Lutz Gissmann [2] conducted research at the University of Freiburg [5] and the Friedrich-Alexander-Universität Erlangen-Nürnberg [6] during the same era. Lutz Gissmann [2] co-authored the same 1983 paper [7], detailing papillomavirus DNA in cervical cancers, a landmark that transformed understanding of HPV's role in cervical oncogenesis and supported histology-based management decisions.

HPV-Centered Prevention era

F. Xavier Bosch[1] is a leading cervical cancer researcher in the HPV-Centered Prevention era, with affiliations at the Institute of Cancer Research[3] and Harvard University[4]. Bosch[1] helped establish that human papillomavirus is a necessary cause of invasive cervical cancer worldwide[6], contributed to the epidemiologic classification of HPV types associated with cervical cancer[7], and highlighted the worldwide prevalence of HPV in cervical cancer[8], laying the evidence base for screening and vaccine initiatives in this era. Chris J.L.M. Meijer[2] is a prominent cervical cancer researcher in the HPV-centered era with affiliations at the Institute of Cancer Research[3] and the Oncode Institute[5]. Meijer[2] has contributed to linking HPV status to cervical lesions and screening outcomes in prospective studies[9], and to translating HPV-type epidemiology into risk-stratified screening through the 2003 HPV type classification[7] and the worldwide prevalence perspective[8].

Biomarker-Driven Precision Therapy era

Mona Saraiya [1], associated with University of California, San Francisco [3] and University of Puerto Rico at Carolina [4], emerged as a leading figure shaping global cervical cancer burden assessment during the Biomarker-Driven Precision Therapy era. Her key contributions in this era are reflected in the papers Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis [7] and Worldwide burden of cervical cancer in 2008 [8], which quantified incidence and mortality and mapped the global disease burden to inform prevention, screening, and resource allocation critical for risk-adapted treatment strategies. Freddie Bray [2], affiliated with Albert Einstein College of Medicine [5] and Heidelberg University [6], contributed to global cervical cancer burden assessments during this era. His contributions, documented in the same two papers [7] [8], provided epidemiological context and trend analyses that underpinned public health planning and biomarker-guided approaches to cervical cancer care in the era.